Comparison of Selective Serotonin Reuptake Inhibitors (SSRIs)
- SSRIs - Selective Serotonin Reuptake Inhibitors
- Brief history
- Mechanism of action
- Indications and uses
- Side effects
- Discontinuation symptoms (withdrawal)
- Drug interactions
- Brief SSRIs comparison table
The most significant class of antidepressants marketed in recent years is the selective serotonin reuptake inhibitors (SSRIs). The six SSRIs available in the United States are:
- citalopram (Celexa)
- escitalopram (Lexapro)
- fluoxetine (Prozac)
- fluvoxamine (Luvox)
- paroxetine (Paxil)
- sertraline (Zoloft)
The SSRIs are the first rationally designed class of psychotropic medications. The strategy behind rational drug development is to design a new drug that is capable of affecting a specific neural site of action (eg, uptake pumps, receptors) while avoiding effects on other site of actions. The goal in such development is to produce agents that are more efficacious, safer and better tolerated than older medications.
All SSRIs are not controlled substances.
Although all SSRI drugs have the same mechanism of action, each SSRI has slightly different pharmacological and pharmacokinetic characteristics. This leads to differences among the SSRIs in their half-lives, clinical activity, side effects, and drug interactions. There are differences between SSRIs that could be clinically significant. Also, SSRIs have very different molecular structures.
The first drug in the SSRI class was Prozac (Fluoxetine), which hit the United States market in 1987. Prozac was FDA approved in December 29, 1987. It is manufactured by Eli Lilly and Company.
Zoloft (Sertraline hydrochloride) was the second SSRI to come to market in the United States, and it was approved by the FDA in December 30, 1991. Zoloft is manufactured by Pfizer Inc.
Paxil (Paroxetine hydrochloride) was the third SSRI to come to market in the United States and was approved by the FDA in December 29, 1992. Paxil is manufactured by GlaxoSmithKline. Chemical structure of Paroxetine differs from other SSRIs by having a piperidine ring.
Luvox (Fluvoxamine maleate) was the next SSRI FDA approved in December 05, 1994. However, now its marketing status is "Discontinued".
Celexa (Citalopram hydrobromide) was approved by the FDA in July 17, 1998. Celexa is manufactured by Forest Pharmaceuticals, Inc.
Lexapro (Escitalopram oxalate) is the newest and most selective of the SSRIs approved by the FDA in August 14, 2002. Lexapro is manufactured by Forest Pharmaceuticals, Inc. Lexapro is a cleaner, improved version of Celexa. It is the active isomer of racemic citalopram.
|Citalopram (Celexa)||Escitalopram (Lexapro)||Fluoxetine (Prozac)||Paroxetine (Paxil)||Sertraline (Zoloft)|
|FDA approval date||July 17, 1998||August 14, 2002||December 29, 1987||December 29, 1992||December 30, 1991|
|Pharmaceutical Forms||10mg, 20mg, 40mg tablets,
oral solution 10 mg/5 mL
|5mg, 10mg, 20mg tablets,
oral solution 5 mg/5 mL
10mg, 20mg, 40mg pulvules,
oral solution 20mg/5mL,
weekly capsules 90 mg
|10mg, 20mg, 30mg, 40mg tablets,
oral suspension 10 mg/5 mL
|25mg, 50mg, 100mg tablets,
oral concentrate 20 mg/mL
|Recommended dose (for Major Depressive Disorder)||20-40 mg/day||10–20 mg/day||10-20 mg/day||20 mg/day||50-100 mg/day|
|Drug interaction potential||Relatively low||Relatively low||High||Moderate to high||Relatively low|
|Most common side effects||Nausea
Sexual dysfunction (ejaculation failure, decreased libido)
|Less common side effects||Tremor
Sexual dysfunction (abnormal ejaculation, decreased libido, impotence)
|Sexual dysfunction (abnormal ejaculation, decreased libido, impotence)
|Half-life||35 hours||27–32 hours||2-4 days||20 hours (highly variable)||26 hours|
|Time to steady-state||7 days||7 days||30 to 60 days||10-14 days||7-14 days|
The brain communicates with itself through the use of special chemicals called neurotransmitters, such as serotonin and norepinephrine. Neurotransmitters carry signals from one nerve cell to another. Research suggests that abnormalities in neurotransmitter activity can affect mood and behavior. Low levels of serotonin and norepinephrine have not been proven to cause depression but it is widely believed that elevation of these chemicals is associated with improvement in mood in depressed people.
All selective serotonin reuptake inhibitors have the same general mechanism of action. SSRIs seem to relieve symptoms of depression by blocking the reabsorption (reuptake) of serotonin by certain nerve cells in the brain. This leaves more serotonin available, which enhances neurotransmission and improves mood. SSRIs are called selective because they seem to affect serotonin significantly more than other neurotransmitters. Thus, the medications work by allowing the body to make the best use of the reduced amounts of serotonin that it has at the time. In due course, the levels of natural serotonin will rise again, and in some instances the SSRI can be reduced and withdrawn.
SSRI antidepressants are at least 10-fold more selective for serotonin reuptake inhibition than for norepinephrine reuptake. However, SSRIs differ in their potency and selectivity in inhibiting serotonin reuptake and many of them have important effects on other transporters and receptors. Each SSRI has a unique profile of multiple pharmacologic actions, which explains the differences in their efficacy and tolerability20.
Binding properties of SSRIs
|Citalopram (Celexa)||most selective serotonin reuptake inhibitor|
|Escitalopram (Lexapro)||most selective serotonin reuptake inhibitor|
|Fluoxetine (Prozac)||least selective serotonin reuptake inhibitor
norepinephrine reuptake 18
dopamine reuptake 18
serotonin-2C receptors 21
cytochrome P450 2D6
cytochrome P450 3A4
|Paroxetine (Paxil)||the most potent serotonin reuptake blocker, but has a low selectivity for the serotonin reuptake
muscarinic cholinergic receptors (most potent blocker of muscarinic receptors among the SSRIs)
histamine H1 receptors
nitric oxide synthase
cytochrome P450 2D6
|Sertraline (Zoloft)||the second most potent inhibitor of serotonin reuptake and the second most selective blocker of serotonin over noradrenaline uptake
dopamine reuptake (more potent dopamine uptake inhibitor than other SSRIs) 22
|Relative Potency for Different Sites of Action for the SSRI Class of Antidepressants - Based on data from Hyttel 1993|
|Figure is taken from De-Spinning In Vitro Data, Sheldon H. Preskorn, M.D.|
All the SSRIs are licensed for major depressive disorder and are considered to be the first-line treatments of depression. They are prescribed more often for elderly patients than any other psychotropics and are the antidepressant of choice for many practitioners.
The SSRIs differ in their licensed indications for non-depression disorders (which differ between countries).
Celexa (Citalopram) licensed indications:
Lexapro (Escitalopram) licensed indications:
- major depressive disorder
- generalized anxiety disorder (GAD)
Paxil (Paroxetine) licensed indications:
- major depressive disorder
- obsessive compulsive disorder (OCD)
- panic disorder
- social anxiety disorder
- generalized anxiety disorder
- posttraumatic stress disorder (PTSD)
Prozac (Fluoxetine) licensed indications:
- major depressive disorder
- obsessive-compulsive disorder
- moderate to severe bulimia nervosa
- panic disorder
In January 2003, Prozac (fluoxetine) was approved by the FDA for the treatment of depression and OCD in children and adolescents who are 7 to 17 years of age.
Zoloft (Sertraline) licensed indications:
- major depressive disorder
- obsessive-compulsive disorder
- panic disorder
- posttraumatic stress disorder
- premenstrual dysphoric disorder (PMDD) in adults (newest indication)
- social anxiety disorder
Clinical trials comparing one SSRI with another indicate that drugs in this class are equally efficacious. Each antidepressant produces approximately a 60% overall response rate (ie, at least a 50% reduction in symptoms as a result of treatment). However, some differences in the SSRIs efficacy exist.
Escitalopram may be superior in efficacy compared with other SSRIs in the treatment of major depressive disorder2. Also escitalopram has better efficacy in the treatment of severe depression than citalopram4.
Paroxetine is the only SSRI indicated for all five anxiety disorders in addition to major depressive disorder.
Interesting and important fact is that SSRI antidepressants are not interchangeable. Persons who discontinue one SSRI for the lack of tolerability or response can be effectively treated with another19.
As a group, the SSRIs possess the following adverse effects:
- sexual dysfunction, including decreased libido, orgasm difficulties, abnormal ejaculation
- dry mouth
- increased appetite
- weight gain
While SSRIs do not appear to differ in overall tolerability, the reported incidences of specific side effects vary. Antidepressants have some different pharmacological characteristics, this means that patients may respond differently to certain SSRIs or experience different side effects with different drugs.
The most common side effect associated with use of SSRIs is nausea. Paroxetine and sertraline have been associated with slightly more cases of nausea.
The SSRIs as a class produce a variety of sexual side effects, including anorgasmia, decreased libido, and impotence. Analysis of the clinical trials suggests that fluvoxamine and fluoxetine are less likely to produce sexual side effects than paroxetine and sertraline. Paroxetine appears to cause the highest rate of sexual dysfunction. Citalopram has been associated with loss of libido and may be associated with a relatively higher level of sexual dysfunction compared with sertraline.
The SSRIs are reported to cause sexual dysfunction in the following descending order of frequency: citalopram 72.7%; paroxetine 70.7%; sertraline 62.9%; fluvoxamine 62.3%; fluoxetine 57.7%28.
Paroxetine produces more delay of orgasm or ejaculation than fluvoxamine, fluoxetine and sertraline 16.
Weight gain is another troubling side effect. The SSRIs vary in their effect on the weight.
Paroxetine, fluoxetine, citalopram and sertraline have been shown
to increase body weight after 6–12 months of administration8.
Fluoxetine and sertraline have the lowest incidence of weight gain during long-term treatment, paroxetine and citalopram higher17.
Paroxetine may cause a significant weight increase, sertraline may cause modest but nonsignificant weight increase with long-term treatment15.
Of the SSRIs, paroxetine may be responsible for the highest risk of weight gain9.
Sertraline is generally associated with a small degree of weight loss in the acute phase of treatment.
Fluoxetine has potent appetite suppressing effects and may cause modest but nonsignificant weight decrease15.
Effects on sleep
SSRIs interfere with sleep architecture. Fluoxetine, paroxetine, and sertraline delay the onset of REM sleep, and fluoxetine and paroxetine increase awakenings and reduce REM sleep, slow-wave sleep, total sleep time, and sleep efficiency. In contrast, sertraline minimally increases sleep efficiency and reduces nocturnal wakefulness time, which may benefit depressed patients with sleep disturbances29.
Paroxetine, like the TCAs desipramine and imipramine, has an in vitro affinity for the muscarinic cholinergic receptor. As a result, paroxetine causes a higher rate of anticholinergic effects, such as dry mouth, constipation, and cognitive disruption, compared with other SSRIs. These effects may be particularly difficult to tolerate for elderly or concomitantly medically ill patients.
Sertraline and fluoxetine are more frequently associated with diarrhea due to their greater specificity for serotonin receptors, while paroxetine has a lower incidence because of its antimuscarinic effects. Recently, sertraline has been shown to cause statistically significantly more diarrhea than other SSRIs7.
Anxiety, agitation, insomnia
Fluoxetine has been associated with highest rate of anxiety and agitation1. Escitalopram and paroxetine are less likely to cause insomnia than fluoxetine and sertraline. Escitalopram and citalopram have been associated with low rates of insomnia, anxiety, and other activating side effects.
The possible increased potential for agitation and/or stimulatory side-effects is difficult to put in perspective, as many agitated or anxious patients tolerate fluoxetine without difficulty and, as with other drugs that have alleged stimulant effects, they may even obtain relief from tension and anxiety. However, if SSRI-induced agitation has previously occurred, then fluoxetine may not be the drug of choice.
Citalopram and paroxetine are more likely to cause dry mouth than escitalopram and fluoxetine.
Paroxetine has been associated with highest rate of drowsiness, somnolence than other SSRIs.
Sertraline and fluoxetine are associated with higher level of headache.
QT interval prolongation
Citalopram has a higher risk of QT interval prolongation than other SSRIs33.
SSRIs aren't considered addictive. However, stopping treatment abruptly or missing several doses can cause discontinuation syndrome accompanied by withdrawal symptoms, including nausea, headache, dizziness, lethargy and flu-like symptoms.
All antidepressants do not have the same type or severity of withdrawal symptoms. Discontinuation syndrome is more common with the SSRIs with shorter half lives and inactive metabolites, such as paroxetine, sertraline, and fluvoxamine. The incidence of discontinuation syndrome is highest with paroxetine followed by fluvoxamine and sertraline. Citalopram and fluoxetine have a lower occurrence of withdrawal symptoms10.
Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine12.
All SSRIs (except paroxetine) are classified as pregnancy Category C, meaning that they may not be safe for use during pregnancy.
Paroxetine (Paxil, Paxil CR) is pregnancy Category D medication. Paroxetine may cause heart defects or serious, life-threatening lung problems in newborn babies whose mothers take the medication during pregnancy.
Marked differences exist between the SSRIs with regard to effects on specific CYP enzymes and, thus, the likelihood of clinically important pharmacokinetic drug-drug interactions.
The potency of the SSRIs as inhibitors of the metabolism of the P450-P2-D6 varies and is reported in descending order of potency as paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine. Fluoxetine and paroxetine are more likely to cause P450 drug interactions than citalopram and sertraline, particularly in combination with medications metabolized by or inhibiting the cytochrome P450 2D6 isoenzyme (e.g., certain antidepressants, phenothiazines, antipsychotics, type IC antiarrhythmics).
Drug interactions with clinical consequences usually involve combinations of an SSRI with other psychotropics, especially monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants, clozapine, lithium, methadone, etc. The interaction between MAOIs and SSRIs is the most important drug interaction limiting SSRI use. This combination may lead to the development of a hyperserotonergic syndrome consisting of excitement, diaphoresis, rigidity, hyperthermia, tachycardia, hypertension, and possibly death. The severity of this interaction necessitates at least 5 week washout when switching a patient from fluoxetine to an MAOI to allow complete elimination of the fluoxetine. At least 14 days should be allowed after stopping citalopram, escitalopram, paroxetine or sertraline before starting an MAOI. This difference in washout time between fluoxetine and citalopram, escitalopram, paroxetine and sertraline when switching from an SSRI to an MAOI is one of the key differences between SSRIs.
Sertraline, citalopram and escitalopram have the lowest potential for drug interactions among the SSRIs, and are to be preferred in patients on other drugs for general medical conditions or if consideration is given to adding an SSRI to other psychotropic medication.
Initial treatment with fluoxetine or paroxetine may not be preferred for patients in whom a potential for a clinically significant drug-drug interaction exists.
The half-life of a drug is the time required to achieve steady-state plasma concentrations (i.e., to metabolize half the dose and lower blood concentrations by 50%). Half-life can be used to estimate how long it will take to clear a drug from the body after treatment is discontinued.
Fluoxetine is unique because of its long half-life and the long half-life of its active metabolite norfluoxetine. Fluoxetine has a half-life of 2-4 days and its active metabolite, norfluoxetine, has a half-life of 4-16 days.
In comparison, citalopram, escitalopram, paroxetine, and sertraline have shorter half-lives in the range of 20-35 hours, and steady-state concentrations (and therapeutic effect) are reached much more rapidly. The long half-life of fluoxetine may blunt the effects of missed doses or treatment discontinuation and makes it easier to discontinue than any of the other SSRIs. On the other hand, fluoxetine requires a much longer washout period than the other SSRIs (several weeks), particularly when switching to monoamine oxidase inhibitors (MAOIs) or TCA.
Antidepressants with relatively short half-lives are desirable for people with multiple comorbidities and complex, multiple-drug regimens because they allow for once-daily dosing. A short half-life enables physicians to switch more rapidly and safely to an alternative antidepressant if treatment fails or if unfavorable drug reactions occur.
Paroxetine and fluvoxamine are more quickly cleared from the body than the other SSRIs.
The possible slower onset of antidepressant action of fluoxetine may be owing to a longer time taken to achieve therapeutic plasma concentrations. In situations where the speed of onset of therapeutic effect is particularly important, such as in severe depression, fluoxetine may not be the SSRI of choice. Patients in whom the long half-life may have advantages (and therefore for whom fluoxetine should be considered) include those who are poorly compliant and those in whom administration less frequent than daily is contemplated.
Sertraline exhibits a sex- and age-dependent half-life. In men, the half-life is approximately 30% shorter (22.4 hr) than in females or the elderly (32.1-36.7 hr).
One of the important differences to note among the SSRIs is whether their pharmacokinetic properties are linear or nonlinear.
Citalopram, escitalopram and sertraline show linear and dose-proportional pharmacokinetics (changes in drug concentration proportional to the change in dose). Plasma concentrations of these drugs are proportional to the daily dose administered and, therefore, predictable.
In contrast, fluvoxamine, fluoxetine and paroxetine have non-linear pharmacokinetics. Higher doses may produce much greater increases in plasma drug concentrations than would otherwise be expected. Thus, increasing the dose of paroxetine or fluoxetine can result in disproportionate and unpredictable increases in plasma levels, half-lives, and ADEs. Titration of fluoxetine and paroxetine doses may therefore be more difficult than with citalopram, escitalopram and sertraline.
Fluoxetine, paroxetine and sertraline are highly protein bound. In contrast, the protein binding of citalopram (50%) and fluvoxamine (77%) is considerably less.
It is difficult to say which antidepressant is the best because each person is different. No one antidepressant is going to be an ideal answer for every person.
Clinically important differences exist between antidepressants for both efficacy and acceptability in favour of escitalopram and sertraline, according to the recent antidepressant meta-analysis reported in The Lancet30.
Sertraline may be the best choice when starting treatment for moderate to severe major depression because it has the most favourable balance between benefits, side effects, and acquisition cost.
A major drawback with escitalopram is a relatively high cost of its generic version. However, European data indicates that escitalopram is the most cost-effective antidepressant compared with other SSRIs31.
The fastest SSRI
Escitalopram has a rapid onset of antidepressant effect and is a good choice when rapid antidepressant response is desirable.
Fluoxetine has the most slow onset of antidepressant action.
The most sedative SSRI
Fluvoxamine and paroxetine are the most sedating of the SSRIs.
The most activating SSRI
Fluoxetine and sertraline are more activating and preferred in depressed patients with apathy, lack of energy, or hypersomnia. And they are least preferred in patients with anxiety and insomnia.
The lowest risk for drug interactions
Sertraline and citalopram have the lowest risk of enzyme inhibition making them the SSRIs of choice in patients at risk for drug interactions.
The best SSRI for anxiety
Escitalopram has potent anxiolytic-like effects32.
The best tolerated SSRI
Escitalopram and sertraline appear to be the best tolerated antidepressants.
For patients with poor compliance with medication or those likely to miss doses or interrupt treatment - fluoxetine is the best SSRI.
- Celexa Prescribing Information Forest Pharmaceuticals, Inc.
- Lexapro Prescribing Information Forest Pharmaceuticals, Inc.
- Paxil Prescribing Information GlaxoSmithKline
- Prozac Prescribing Information Eli Lilly and Company
- Zoloft Prescribing Information Pfizer Inc.
- 1. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005 Mar;38(2):69-77 MedLine
- 2. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006 Mar;31(2):122-31. MedLine
- 3. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001 Dec 19;286(23):2947-55
- 4. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder Encephale. 2004 Mar-Apr;30(2):158-66.
- 5. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000 Aug;59(2):119-26.
- 6. Labbate LA. Sex and serotonin reuptake inhibitor antidepressants. Psychiatr Ann. 1999;29:571–9.
- 7. Meijer WE, Heerdink ER, van Eijk JT, Leufkens HG. Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf. 2002;11:655–62. PubMed
- 8. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl.):37–41. PubMed
- 9. Fergunson JM. SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion. J Clin Pschiatry. 2001;3:22–7.
- 10. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997;58
- 11. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006 Apr;60(4):482-91. PubMed
- 12. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998 Jul 15;44(2):77-87. PubMed
- 14. Ian M. Anderson and J. Guy Edwards. Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness Advances in Psychiatric Treatment (2001) 7: 170-180
- 15. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000 Nov;61(11):863-7.PubMed
- 16. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997 Fall;23(3):176-94. PubMed
- 17. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004 Oct;65(10):1365-71. PubMed
- 18. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61.
- 19. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999 Sep;60(9):574-9.
- 20. Stahl SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 1998;59:343-4. Psychiatrist
- 21. Owens JM, Knight DL, Nemeroff CB. Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Encephale. 2002 Jul-Aug;28(4):350-5. PubMed
- 22. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023-9. PubMed
- 23. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999 Apr;57(4):507-33.
- 24. Geretsegger C, Bo"hmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol. 1994 Spring;9(1):25-9.
- 25. Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol. 1999 Sep;14(5):259-75. PubMed
- 26. Clinical Pharmacology of SSRI's. How SSRIs as a Group Are Similar. Sheldon H. Preskorn, M.D.
- 27. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004 Mar;65(3):405-13 PubMed
- 28. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21. PubMed
- 29. Winokur A, Lexon N, Allen K, and et al. Sertraline administered for 8 weeks to depressed patients did not alter sleep architecture: a preliminary report. New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 24, 1994
- 30. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746-58.
- 31. Mencacci C, Aguglia E, Biggio G, Cappellari L, Di Sciascio G, Fagiolini A, Maina G, Tortorella A, Katz P, Ripellino C. C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy. Adv Ther. 2013 Jul;30(7):697-712.
- 32. Fish EW, Faccidomo S, Gupta S, Miczek KA. J Pharmacol Exp Ther. 2004 Feb;308(2):474-80.
- 33. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014 May;75(5):e441-9. PubMed
Published: May 05, 2007
Last updated: February 17, 2016